JASON ROBERT WESTIN to Benzimidazoles
This is a "connection" page, showing publications JASON ROBERT WESTIN has written about Benzimidazoles.
Connection Strength
0.118
-
University of Chicago phase II consortium trial of selumetinib (MEKi) demonstrates low tolerability and efficacy in relapsed DLBCL. Br J Haematol. 2018 04; 181(2):264-267.
Score: 0.118